A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)

Leukemia

Volumn 27, Issue 7, 2013, Pages 1610-1613

  Sardnal, V ^a   Rouquette, A ^b   Kaltenbach, S ^c   Bally, C ^d   Chesnais, V ^e,f   Leschi, C ^e,f   Ades, L ^d   Santini, V ^g   Park, S ^a   Toma, A ^h   Fenaux, P ^d   Dreyfus, F ^a   Fontenay, M ^a,e,f   Kosmider, O ^a,e,f  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔTEL DIEU   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d AVICENNE HOSPITAL   (France)

^e INSTITUT COCHIN   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITY OF FLORENCE   (Italy)

^h HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BIOLOGICAL MARKER; CEREBLON; CULLIN; DNA BINDING PROTEIN; DNA DAMAGE BINDING PROTEIN 1; EPOETIN ALPHA; GENOMIC DNA; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; NUCLEOTIDE; RECOMBINANT ERYTHROPOIETIN; RNA; THALIDOMIDE; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ALLELE; ANEMIA; BONE MARROW; CANCER PATIENT; CHROMOSOME 5Q; CHROMOSOME DELETION; CHRONIC MYELOMONOCYTIC LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; CYTOPENIA; CYTOTOXICITY; DNA POLYMORPHISM; DRUG EFFICACY; DYSPLASIA; ERYTHROCYTE TRANSFUSION; EXON; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOMODULATION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LETTER; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TERATOGENICITY; TRISOMY 8; UPREGULATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHROMOSOME DELETION; HUMANS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PEPTIDE HYDROLASES; POLYMORPHISM, GENETIC; RISK; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 84880278470     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.59     Document Type: Letter

References (15)

1. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327: 1345-1350.
2. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26: 2326-2335.
3. Andhavarapu S, Roy V. Immunomodulatory drugs in multiple myeloma. Expert Rev Hematol 2013; 6: 69-82.
4. Adè s L, Fenaux P. Immunomodulating drugs in myelodysplastic syndromes. Am Soc Hematol Educ Program 2011; 2011: 556-560.
5. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
6. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86-93.
7. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771-4779.
8. Broyl A, Kuiper R, van Duin M, van der Holt B, El Jarari L, Bertsch U et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013; 121: 624-627.
9. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958-965.
10. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusiondependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765-3776.
11. Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R et al. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood 2012; 120: 3419-3424.
12. Gandhi AK, Avet-Loiseau H, Waldman M, Thakurta A, Aukerman SL, Chen G et al. Detection and quantification of cereblon protein and mRNA in multiple myeloma cell lines and primary CD138+multiple myeloma cells. ASH 2012, (abstract #4043).
13. Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008; 5: e35.
14. Sugimoto Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A et al. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol 2012; 5: 4.
15. Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene 2013; 32: 1110-1120.